



HAL
open science

Returning to Care after Incarceration with HIV: The French Guianese Experience

F. Huber, S. Vandentorren, A. Merceron, T. Bonifay, A. Pastre, A. Lucarelli,
M. Nacher

► **To cite this version:**

F. Huber, S. Vandentorren, A. Merceron, T. Bonifay, A. Pastre, et al.. Returning to Care after Incarceration with HIV: The French Guianese Experience. BMC Public Health, 2020, 20 (1), pp.754. 10.1186/s12889-020-08772-9 . hal-03833307

HAL Id: hal-03833307

<https://hal.sorbonne-universite.fr/hal-03833307>

Submitted on 2 Nov 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

RESEARCH ARTICLE

Open Access



Returning to care after incarceration with HIV: the French Guianese experience

F. Huber^{1,2*} , S. Vandentorren³, A. Merceron⁴, T. Bonifay⁵, A. Pastre⁵, A. Lucarelli⁶ and M. Nacher⁷

Abstract

Background: HIV prevalence in correctional facilities may be 2 to 10 times higher than in the general adult population. Antiretroviral therapy (ART) interruption is frequent after an incarceration. This, in combination with post-release high-risk behaviors, may have detrimental consequences on the epidemic. Although return to care after release from correctional facilities has been described in many North American settings, data from South America seemed scarce.

French Guiana is the only French territory located in South America. In 2014, HIV prevalence was estimated at 1.2% among pregnant women and oscillated around 4% in the only correctional facility.

Method: HIV-infected adults released from the French Guiana correctional facility between 2007 and 2013 were included in a retrospective cohort survey. The first objective was to describe the cascade of care in the 4 years following release. The secondary objectives were to describe contacts with care and to identify factors associated with return to HIV care, 1 year after release.

Results: We included 147 people, mostly males (81.6%). The median time before the first ambulatory consultation was 1.8 months. Within 1 year after release, 27.9% came for unscheduled emergency consultations, 22.4% were hospitalized. Within 4 years after release, 40.0–46.5% were in care, 22.4% achieved virological success. Being on ART when incarcerated was associated with HIV care (aIRR: 2.0, CI: 1.2–3.0), whereas being HIV-diagnosed during the last incarceration was associated with poor follow-up (aIRR: 0.3, CI: 0.1–0.9).

Conclusion: The risk of HIV-follow-up interruption is high, after an incarceration with HIV. ART supply should be sufficient to cover the timespan following release, several months if possible. Those not on ART at the time of incarceration may require special attention, especially those newly HIV-diagnosed while in custody. Comprehensive programs are necessary to support ex-offenders to stay on ART after incarceration.

Keywords: HIV, Prison, Antiretroviral therapy, Ambulatory care

Background

People in prisons and other closed settings are identified as key populations for HIV risk acquisition by WHO. Indeed, HIV prevalence in correctional facilities may be 2 to 10 times higher than in the general adult population [1]. With more than 11 million people incarcerated in

2016, the most vulnerable to HIV acquisition are over-represented in correctional facilities [2, 3]. Post-release high-risk behaviors, combined with antiretroviral therapy (ART) interruption, may have a strong impact on the general population, thus, keeping HIV under control after incarceration is strategic from a public health perspective [4, 5].

French Guiana is the only French territory located in South America, between Surinam and Brazil. In 2014, HIV prevalence was estimated at 1.2% among pregnant women and oscillated around 4% in the only correctional

* Correspondence: flo.dawei@gmail.com

¹COREVIH Guyane, Centre Hospitalier Andree Rosemon, Cayenne, Guyane Française, France

²Réseau Kikiwi, Cayenne, Guyane Française, France

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

facility. In French Guiana's prison, HIV prevalence is around twice the prevalence of the French mainland prisons, and around four times the prevalence in the region. We estimated that 4.5 to 5.0% of people living with HIV (PLWHIV) experienced one incarceration or more between 2007 and 2013 [3].

Recently, we pointed that the socioeconomic situation of HIV-infected inmates was particularly precarious, relative to other detainees [3], and that the male standardized mortality ratio after release was very high, reaching 14.8 times the age-specific mortality rates for males in French Guiana [6].

Although retention in HIV care after release from correctional facilities has been described in many North American settings, data from South America seems scarce [7]. The situation in French Guiana was hypothesized to be singular and warrant investigation because of the low density of health professionals, the poverty of a large segment of the population, and the intense migratory movements between low and middle income HIV-endemic countries and this French territory with half of the adult population being foreigners. Moreover, although some studies in the USA have suggested benefits for some interventions to improve return to care, a large randomized control trial failed to show any difference between traditional case management and transitional case management interventions [8, 9]. This suggests that there is a need to identify people with the highest risk of falling out of care in order to target them for comprehensive interventions.

To better understand the prognosis and outcomes of people living with HIV released from French Guiana's correctional facility, we conducted a retrospective cohort survey.

The first objective of this study was to describe the linkage to HIV care and the cascade of care in the 4 years following release.

Secondary objectives were to describe the contact with health care and to study the factors associated with return to HIV care, 1 year after release.

Methods

Study setting

French Guiana's sole correctional facility includes a prison for males (« centre de détention », for persons sentenced for more than 2 years), a jail for males and a jail for women (« maison d'arrêt », for persons waiting for trial or sentenced for a duration shorter than 2 years) [6].

HIV testing and ARV treatments are proposed to any incarcerated patients, according to the French National recommendations [10]. Before the last recommendation issued at the end of 2013, the threshold to start ART was 500 CD4 cells/mm³ [11]. After HIV positive confirmation, all HIV-positive patients were registered in

the electronic medical record NADIS, used at the regional level for HIV-follow-up, and gave written consent for electronic data entry, data analysis, and research publication. NADIS on-line software was shared and available for any HIV specialist working in French Guiana.

After release, the PLWHIV were given a follow-up appointment in a specialized care unit, usually in one of the 3 main hospitals of the territory, within 7 days following release. They received a one-week provision of ART.

The DAI-VIH retrospective cohort

The DAI-VIH retrospective cohort was conducted among all the HIV-infected adults (> 18 years old) released between 1/1/2007 and 12/31/2013, after an incarceration of 1 month or more. The last incarceration of the time period was defined as incarceration of reference [6].

The main source of data was the electronic medical records NADIS. Additional data were collected from the correctional facility paper files, the registries of the three regional hospitals, and the municipal death registries of the main towns of French Guiana (covering 80% of the French Guianese population). Identification relied on name and date of birth and was performed by a medical doctor. Data were recorded manually and anonymized, by the same person.

The data collected were socio-demographic characteristics, number of past incarcerations, date of entry and release of the index incarceration, medical and psychiatric background, substance abuse, HIV history, comorbidity, HIV-clinical stage, opportunistic infections, immunological and virological results during the index incarceration, post-release events: consultation in HIV care units, unscheduled emergency consultations, hospitalizations, occurrences of opportunistic infections or any CDC-stage C events, further incarcerations, date and cause of death.

"Returned to HIV care" was defined as being in care for HIV after release, whether it was in an ambulatory unit, or following a hospitalization or a new incarceration. "Undetectable viral load" was defined as an HIV viral load (VL) < 50 copies/ml. Patients were considered as "in HIV care" within a period of time, if an undetectable VL was documented, whether a HIV follow-up consultation was registered or not during the same interval. More detailed information (methodology of the DAI-VIH cohort, duration of the index incarceration, characteristic of the study population ...) have already been published [6].

We used Poisson regression with robust variance, as this method is a good alternative for the analysis of cross-sectional studies with binary outcomes, with resulting estimates close to those obtained from the Mantel Haenszel procedure [12]. Covariable were

included in the final model after bivariate analyses, if $p < 0.2$. Statistical analyses were performed with Stata 11 (Stata Corporation, college station, Texas, USA).

The protocol was approved by the Ethics Committee of Cayenne Hospital, and the data base was declared to the Commission Nationale de l'Informatique et des Libertés (CNIL), under the number 1975083v0.

Results

All the PLWHIV with the inclusion criteria were included in the DAI-VIH cohort ($n = 147$). They had an observational period of one to 7 years after release. The median time since the index incarceration was 9 months.

The majority were males (81.6%), migrants (68.7%), with a median age at 37.3 years (mean: 37.8, CI: 36.3–39.2). The socio-economic status was low, 25.8% were homeless and 34% were crack-cocaine users. Most patients had an early stage HIV infection (78.1% CDC-stage A). On release, 50.3% were on ART. Reasons for not being treated were not fulfilling the criteria for 74.6% and refusing for 15.1%. Among those treated, 81.3% were virologically suppressed (viral load < 50 copies/mL) [6].

Return to HIV care after release

As seen Tables 1, 70.1% of the included patients returned to HIV care after release. It was in an ambulatory department for 51.0% ($n = 75$), or after being hospitalized (12.2%, $n = 18$), or re-incarcerated (6.1%, $n = 9$). No consultation with an HIV physician had been documented for 29.9% of the formerly incarcerated persons.

For those who linked to the ambulatory HIV department at any time, ($n = 75$), the median time between release and first consultation was at 1.8 months (mean: 6.7, inter quantile range (IQR): 0.5–8.2). It was shorter for patients on ART at release: median 1.5 months (mean: 3.5, IQR: 0.4–2.6), compared to PLWHIV

released without ART: median 9.1 month (mean 13.8, IQR: 2.0–16.9).

Among the 147 included persons, in the 90 days following release, 36.1% (53/147) returned to HIV care, 31.3% declared to be on ART (46/147), 12.9% had a documented undetectable viral load (19/147).

As seen in Fig. 2, over a period of 4 years (± 3 months), the proportion of patients in HIV care fluctuated between 40.0 and 46.5% after M6 (± 3). After the first 6 months, this was relatively stable over time, as for those who declared to be on ART, which fluctuated between 35.0 and 36.8%.

Overall, 41.5% ($n = 61$) of patients reached an undetectable viral load (Fig. 1) at any time during the post-release period, but the virological control was not stable over time for many of them, explaining why the proportion in success for each interval was far below this number. Nevertheless, virological control seemed to be slowly improving, reaching 22.4% of the cohort, 4 years after release (Fig. 2).

Restricting the analysis to those who declared to be on ART in the interval, the proportion virologically suppressed was at 49.1% at 1 year, 58.1% at 2 years, 55.3% at 3 years and 61.3% at 4 years.

Contact with the health care system, excluding HIV care


Whether followed in specialized care or not, a high proportion of patients had contacts with hospital care. Thus, at 12 ± 3 months following release, 27.9% ($n = 41$) had an unscheduled emergency consultation, 22.4% ($n = 33$) had been hospitalized, and 7.5% ($n = 11$) were diagnosed with an opportunistic infection. Besides that, 10.9% ($n = 16$) were reincarcerated and 2.7% ($n = 4$) died. Within the 2 years following release, 34.1% (42/123) had an unscheduled emergency consultation.

Table 1 Factors associated with being in HIV care at 12 ± 3 months, after release from French Guiana correctional facility ($n = 132$)

	HIV care (%)		Crude IRR (95%CI)	p	Adjusted IRR (95%CI)		p
	Yes ($n = 59$)	No ($n = 73$)					
Chronology between ART and incarceration							
- No ART on release	25.7	74.3	Reference		Reference		
- ART started/restarted in prison	50.0	50.0	1.9 (1.1–3.4)	0.02	1.4 (0.8–2.4)		0.20
- On ART while incarcerated	79.4	20.6	3.1 (2.0–4.8)	< 0.01	2.0 (1.2–3.0)		< 0.01
Advanced HIV disease*	67.3	32.7	2.1 (1.5–3.1)	< 0.01	1.5 (1.0–2.1)		0.04
Chronology between 1st positive HIV-test and incarceration							
- Diagnosed outside custody	63.6	36.4	Reference		Reference		
- Diagnosed in custody, before the last incarceration	42.0	58.0	0.7 (0.4–1.0)	0.03	0.8 (0.6–1.2)		0.35
- Diagnosed during the last incarceration	11.1	88.9	0.2 (0.5–0.8)	< 0.01	0.3 (0.1–0.9)		0.03

*Defined by: previous AIDS illness (CDC stage C), or CD4 nadir < 200/mm³

Cofactors tested but not retained after final analysis ($p > 0.20$) were: addiction, duration of the index incarceration, homelessness. Cofactors retained in the final analysis ($p < 0.20$) but not in the final model were: sex, re-incarceration, co-morbidity, psychiatric background, native from Surinam




Return to care 1 year (12 +/- 3 months) after release

As seen in Fig. 3, between 70 to 80% of people already on ART when incarcerated were in care at 1 year +/- 3 months and were on ART without interruption. A few patients among the latter came to renew their prescription without any medical consultation or lab test. Indeed, only 15% had a documented uninterrupted viral

load < 50 copies/mL, the majority of those not on ART when incarcerated had no medical follow-up and were not on ART at 1 year +/- 3 months after release, even if taking ART in custody. The latter had frequent care or treatment interruptions.

After excluding re-incarcerated patients, and those who died, 44.7% (59/132) returned to HIV care at 1 year,






Fig. 3 Care events, 1 year (+/- 3 months) after release from the French Guiana correctional facility (%; $N = 144$). « Uninterrupted »: at least one event in the 3 months following release, plus one event at M6+/- 3, plus one event at M12+/- 3. Re-incarcerated and loss to follow-up people were included, but not deaths.

25.7% (18/70) among those released without ART, 50.0% (14/28) among those who start or restarted ART while incarcerated, and 79.4% (27/34) among those already on ART when incarcerated ($n = 132$). Only a minority of patients released without ART declared to be on ART ($n = 6$) or were virologically suppressed ($n = 3$) after release.

We explored the factors associated with being in care 1 year after release, excluding those who died and those re-incarcerated within this time-period ($n = 132$).

As seen in Table 1, ART was the strongest factor associated with linkage to care: patients already on treatment while incarcerated had the best outcomes (adjusted IRR: 2.0, CI: 1.2–3.0), followed by those for whom ART was introduced or re-introduced while incarcerated, although the latter group variable was no longer significant in the multivariate analysis (aIRR: 1.4, CI: 0.8–2.4).

Being diagnosed with an advanced HIV-infection was also associated with return to care (aIRR: 1.5, CI: 1.0–2.1), whereas being HIV-diagnosed during the last incarceration seemed associated with care discontinuation (aIRR: 0.3, CI: 0.1–0.9). Factors tested but not retained in the final model were: age, sex, country of birth, drug or alcohol consumption, psychiatric disorder, comorbidity, homelessness, previous incarceration, and duration of the index incarceration.

Discussion

Long delay to return to HIV-care, despite frequent unscheduled emergency consultations

Patients on ART left prison with a 1-week supply and returned to care after a median 45 days, we thus assume that a vast majority had interrupted treatment.

Significant delays until the first HIV-ambulatory care visit has also been reported in North American studies [13, 14]. Seeking for ambulatory care may not be the

priority for formerly incarcerated persons. In addition to significant psychosocial barriers to care [3, 6, 13, 15, 16], they may also have different representations and attitudes towards health, time and forward planning for consultations. Thus, drug shortages are frequent [14, 17, 18].

Longer ART provision has been delivered in French Guiana, in the light of our data. Ideally several months of supply should be delivered, using single-tablet regimens with a high genetic barrier therapy [19].

In our survey, around one third came for an unscheduled emergency consultation within 2 years after release. Despite the poor retention in HIV-care, formerly incarcerated persons have frequent contacts with hospital care for emergency purposes, often in relation to homelessness and recent drug use [13, 20]. Ideally, emergency departments should be strategic places to identify and refer lost-to-follow-up PLWHIV.

Poor retention in care and lost benefits after release, an old issue

For those treated in correctional facilities, viral suppression on ART is generally observed, sometimes surpassing those in the non-incarcerated population. Nevertheless, virological suppression is often not sustained after release [3, 7, 18, 19, 21], mortality is high [6, 22] and retention in care is poor [17, 23–25].

The proportion of patients who returned to care at 90 days post-release was of similar magnitude (36.1%) than in the Texas department of criminal justice (28%) [24], in Dallas county jail (34%) [26], in the Philadelphia prison system (29.4%) [27]. In contrast, in Connecticut (60.7%) [25], Rhode Island (43%), and North Carolina (49%) [14], the proportion of persons returning to care was higher than in French Guiana.

Six months after release, the USA 10-multisite EnhanceLink Initiative reported a sustained retention in care for 38%, *sustained retention* being defined as having a clinic visit during each quarter in the 6 month post-release period [23]. In Wisconsin, 67% of PLWHIV were linked to HIV care within 180 days in a recent observational survey [28].

One year after release, 24.7% of the formerly incarcerated HIV-positive persons were in care in the Philadelphia prison system [27], 67% in Connecticut [29]. Our result was in between, at 45.8%.

Although most surveys reported early return to care indicators, at 90 days or less, we assume that data at 6 months or more may be more relevant, given delays to return: in French Guiana, the proportion in HIV care was 36.1% at 3 month, and 44.8% at 6 months.

Factors associated with return to HIV care

It has been shown that poor retention in HIV care predicts poor survival [30, 31], thus, it is unsurprising to find a poor retention, and a high rate of mortality among former HIV-infected [6, 22].

Some risk factors identified in our study were consistent with previous surveys: being diagnosed with an advanced HIV-infection was correlated with returning to care at 1 year, in our survey (aIRR: 1.5, CI: 1.0–2.1) whereas HIV-only status was a predictor of low retention in a North Carolina statewide study [31].

Like in French Guiana, receiving ART while incarcerated was associated with return to care in Texas [24] and Connecticut [29]. Other surveys showed that receiving ART in custody was associated with early linkage and retention in care [24, 25, 32]. However, the impact may differ, between patients on ART when incarcerated, and those starting or restarting ART in prison. In our experience, and perhaps other's, most of the latter were not in HIV care 1 year after release [26].

Hence patients *not on ART* when incarcerated may require greater attention and support for release preparedness and linkage to care.

In addition, receiving the HIV-diagnosis in custody negatively impacted the linkage to care 1 year after release in our setting. Although this has not been explicitly described elsewhere, it is in line with previous surveys [33]. In contrast, prior HIV clinic follow-up before incarceration was a strong predictor of linkage to care within 90 days of release from Dallas country jail [26], and those not previously in care had longer linkage times to care in Rhode Island and North Carolina [14].

Being HIV-diagnosed while incarcerated may be a proxy for a behaviorally distinct group of patients, notably less health-conscious, or less likely to adhere to the constraints of scheduled care. People HIV-diagnosed in custody may also be more marginalized and socially

vulnerable than others (in our experience, they are more often migrants [3]).

Besides that, diagnosis in Prison may impact the post-release relation to care. In French Guiana, HIV ambulatory units offer a comprehensive package of care, including counselling, health education, psychological support, by experienced multidisciplinary team (nurses, social workers, psychologist) where newly diagnosed people are repeatedly seen. The situation is different for those diagnosed in correctional facility, often left alone to cope with the shock and distress after receiving the HIV diagnosis. Indeed, patients frequently describe custody as a hostile environment, with concerns about confidentiality and lack of friendly support. As elsewhere, HIV-related stigma segregation are common [34]. Furthermore, newly diagnosed persons may be reluctant to consult an unknown ambulatory unit after release.

Unlike other studies [26], psycho-social vulnerability factors like drug use and homelessness, were not associated with poor return to care in our survey. This may be due to our methodology, as we decided to conduct multivariate analysis after excluding people reincarcerated within the year following release.

Indeed, multiple incarcerations are often associated with drug-use and homelessness [6, 35]. Re-incarcerations may have a protective effect for the triple burden subpopulation “homeless-addicted-multi-incarcerated”, through access to care and re-initiation of ART while incarcerated [25]. With our methodology, we probably underestimate the effect of the “homeless-addicted-multi-incarcerated” subpopulation.

Minorities, like black and latinos had sometimes poorer outcomes in terms of return to care [14, 36], although this is controversial [26]. We were not able to investigate these factors as racial statistics are not allowed in the French Law. Nevertheless, we found no impact of the country of birth after multivariate analysis.

Improving the linkage to care of formerly incarcerated HIV-positive patients

In 2001, through the experience of the Project Bridge Program held in Rhode Island (USA), Rich stated that formerly incarcerated HIV-positive persons could stay in care when given adequate support [37]. Since then, observational data showed that many interventions were efficient: transitional case management [25, 38, 39], discharge planning [23, 24, 40], provision of post-release housing [40], HIV education [23], transportation assistance [23], navigation program [28].

Some recent interventions seemed to have favorable impacts: patient navigation program combined with enhanced case management [36], peer navigation intervention [41], telephone contact by a continuity clinic coordinator [42]. However, a recent large study did not

show any difference between routine discharge planning and the ImPACT intervention [8, 9]. Thus there is a need to identify people at highest risk of interrupting care after release to target them for comprehensive interventions [8].

Given the similarity of many of our results to those described in the USA, we could implement these US experiences, and advocate to reinforce the five necessary components described by Springer and al to improve the transition to community care: case management services, continuity of ART, treatment of the substance use disorder, continuity of treatment for mental illness, and reducing HIV-associated risk-taking behavior [16]. Furthermore, maintaining contact with care givers through cellphone provision, may be an affordable pragmatic intervention to test in French Guiana.

Limitations and strengths of our study

The small sample size, and the retrospective nature of the study are limitations. Information recorded from the medical files may have been interpreted inaccurately, as it was not standardized. Besides this, non-medical confounding factors (like health coverage, educational status ...) were not always available. We cannot exclude a bias due to loss of follow-up as well, as we found no information for 22.4% of the patients after their release. As they were mostly migrants, some may have returned to care in a neighboring country.

Furthermore, our study cannot pretend to explain the overall dynamics of return to care at different time points. Indeed, some factors associated with HIV care at 12 months differed when the outcome was uninterrupted care (Supplementary table).

The strength of our cohort is that with 56.5% of persons initiating ART in prison there was a balance between pretreated and non-pretreated persons, which seemed to be an interesting segmentation in terms of outcome, a distinction that is usually absent from other studies [6].

Conclusions

Despite the virological benefits while incarcerated for those on ART, a high rate of formerly incarcerated HIV-positive persons released from the French Guiana Correctional facility died soon after release [6] and return to care was poor.

Our study highlights some key facts already described the North American surveys, which may lead to pragmatic recommendations.

Indeed, test and treat strategy may have a strong effect for the retention in care for formerly incarcerated HIV-positive persons and may be advice whenever feasible.

Formerly incarcerated persons take time to return to ambulatory HIV care, meaning a high risk of drug shortage.

Formerly incarcerated persons may come frequently to the hospital for unscheduled emergency consultations. Identifying and referring these patients back to ambulatory HIV care may improve return to care after release.

Being already on ART at the time of incarceration seems strongly associated with returning to care after release; those *not on ART* when incarcerated may require more support than others, as well as those newly HIV-diagnosed in custody.

Supplementary information

Supplementary information accompanies this paper at <https://doi.org/10.1186/s12889-020-08772-9>.

Additional file 1.

Abbreviations

ART: Anti-retroviral therapy; PLWHIV: People living with HIV; VL: Viral load

Acknowledgments

We warmly thank Valerie Ho-Bin-Wang (UCSA), François Lacapère (ARS Guyane) and the Réseau Kikiwi for their support, and all the patients included in the study.

Authors' contributions

FH, AM: conception, acquisition of the data. FH, SV, MN: design of the work. FH, AM, SV, MN: analysis, interpretation of data. FH, AM, AM, TB, AP, AL, MN: drafted the work or substantively revised it. All Authors read and approved the manuscript.

Author's information

FH (MD, MPH) is specialized in infectious diseases, involved in the care of people infected with HIV, at the French Guiana correctional facility, since 2013.

Funding

No funding was received to conduct this study.

Availability of data and materials

Data can be requested from the corresponding author.

Ethics approval and consent to participate

The protocol was approved by the Ethics Committee of Cayenne Hospital, and the data base was declared to the Commission Nationale de l'Informatique et des Libertés (CNIL), under the number 1975083v0. Participants signed a consent form to be included in the analysis.

Consent for publication

Not applicable.

Competing interests

Authors declare that they have no competing interests.

Author details

¹COREVIH Guyane, Centre Hospitalier Andree Rosemon, Cayenne, Guyane Française, France. ²Réseau Kikiwi, Cayenne, Guyane Française, France. ³Département d'épidémiologie sociale, INSERM, Sorbonne université, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), Paris, France. ⁴Université des Antilles et de la Guyane, Faculté de Médecine Hyacinthe Basturaud, Pointe-à-Pitre, France. ⁵UCSA, Centre Hospitalier Andree Rosemon, Cayenne, Guyane Française, France. ⁶Hôpital de Jour Adulte, Centre Hospitalier Andree Rosemon, Cayenne, Guyane Française, France. ⁷Inserm CIC

Antilles-Guyane INSERM 1424 (Pole Guyane), Universite de Guyane, Cayenne, France.

Received: 26 January 2020 Accepted: 24 April 2020

Published online: 24 May 2020

References

- Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key Populations - 2016 Update. Geneva, Switzerland: World Health Organization; 2016. Available from: https://www.ncbi.nlm.nih.gov/books/NBK379694/pdf/Bookshelf_NBK379694.pdf. Cited 2019 Nov 9.
- Focus on HIV in prisons vital to end AIDS WHO; Available from: <https://www.who.int/hiv/mediacentre/news/hiv-in-prison-2017/en/>. Cited 2019 Apr 3.
- Huber F, Vandentorren S, Merceron A, Chaponnay A, Gadio G, About V, et al. HIV-positive in the darkness of a correctional facility: more vulnerable and less treated. *Int J STD AIDS*. 2019;10:095646241881645.
- Adams JW, Lurie MN, King MRF, Brady KA, Galea S, Friedman SR, et al. Potential drivers of HIV acquisition in African-American women related to mass incarceration: an agent-based modelling study. *BMC Public Health*. 2018;18(1):1387.
- Ojikutu BO, Srinivasan S, Bogart LM, Subramanian SV, Mayer KH. Mass incarceration and the impact of prison release on HIV diagnoses in the US South. *Selvey LA. PLoS One*. 2018;13(6):e0198258.
- Huber F, Merceron A, Madec Y, Gadio G, About V, Pastre A, et al. High mortality among male HIV-infected patients after prison release: ART is not enough after incarceration with HIV. *PLoS One*. 2017;12(4):e0175740.
- Iroh PA, Mayo H, Nijhawan AE. The HIV care Cascade before, during, and after incarceration: a systematic review and data synthesis. *Am J Public Health*. 2015;105(7):e5–16.
- Wohl DA, Golin CE, Knight K, Gould M, Carda-Auten J, Groves JS, et al. Randomized controlled trial of an intervention to maintain suppression of HIV Viremia after prison release: the imPACT trial. *JAIDS J Acquir Immune Defic Syndr*. 2017;75(1):81–90.
- DiPrete BL, Pence BW, Golin CE, Knight K, Flynn PM, Carda-Auten J, et al. Antiretroviral adherence following prison release in a randomized trial of the imPACT intervention to maintain suppression of HIV Viremia. *AIDS Behav*. 2019;23(9):2386–95.
- France, Ministère des affaires sociales et de la santé (2012), Morlat P. Prise en charge médicale des personnes vivant avec le VIH Rapport 2013: recommandations du groupe d'experts. Paris: DILA - Direction de l'information légale et administrative : La documentation française; 2013.
- France, Ministère de la santé et des sports (2009–2010), Yéni P. Prise en charge médicale des personnes infectées par le VIH: rapport 2010 [au Ministère de la santé et des sports] : recommandations du groupe d'experts. Paris: la Documentation française; 2010.
- Barros AJ, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. *BMC Med Res Methodol*. 2003;3(1):21.
- Khanna S, Leah J, Fung K, Antoniou T, Kouyoumdjian F. Health care utilization by people with HIV on release from provincial prison in Ontario, Canada in 2010: a retrospective cohort study. *AIDS Care*. 2018;12:1–8.
- Montague BT, Rosen DL, Sammartino C, Costa M, Gutman R, Solomon L, et al. Systematic assessment of linkage to Care for Persons with HIV released from corrections facilities using existing datasets. *AIDS Patient Care STDs*. 2016;30(2):84–91.
- Kouyoumdjian FG, Cheng SY, Fung K, Orkin AM, Mclsaac KE, Kendall C, et al. The health care utilization of people in prison and after prison release: a population-based cohort study in Ontario, Canada. *PLoS One*. 2018;13(8):e0201592.
- Springer SA, Spaulding AC, Meyer JP, Altice FL. Public health implications for adequate transitional care for HIV-infected prisoners: five essential components. *Clin Infect Dis*. 2011;53(5):469–79.
- Baillargeon J, Giordano TP, Rich JD, Wu ZH, Wells K, Pollock BH, et al. Accessing antiretroviral therapy following release from prison. *JAMA*. 2009; 301(8):848–57.
- Springer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2004;38(12):1754–60.
- Meyer JP, Cepeda J, Springer SA, Wu J, Trestman RL, Altice FL. HIV in people reincarcerated in Connecticut prisons and jails: an observational cohort study. *Lancet HIV*. 2014;1(2):e77–84.
- Boyd AT, Song DL, Meyer JP, Altice FL. Emergency department use among HIV-infected released jail detainees. *J Urban Health*. 2015;92(1):108–35.
- Davies NECG, Karstaedt AS. Antiretroviral outcomes in south African prisoners: a retrospective cohort analysis. *PLoS One*. 2012;7(3):e33309.
- Loeliger KB, Altice FL, Ciarleglio MM, Rich KM, Chandra DK, Gallagher C, et al. All-cause mortality among people with HIV released from an integrated system of jails and prisons in Connecticut, USA, 2007–14: a retrospective observational cohort study. *Lancet HIV*. 2018;5(11):e617–28.
- Althoff AL, Zelenev A, Meyer JP, Fu J, Brown S-E, Vagenas P, et al. Correlates of retention in HIV care after release from jail: results from a multi-site study. *AIDS Behav*. 2013;17(Suppl 2):S156–70.
- Baillargeon JG, Giordano TP, Harzke AJ, Baillargeon G, Rich JD, Paar DP. Enrollment in outpatient care among newly released prison inmates with HIV infection. *Public Health Rep*. 2010;125(Suppl 1):64–71.
- Loeliger KB, Altice FL, Desai MM, Ciarleglio MM, Gallagher C, Meyer JP. Predictors of linkage to HIV care and viral suppression after release from jails and prisons: a retrospective cohort study. *Lancet HIV*. 2017;27.
- Ammon B, Iroh P, Tiruneh Y, Li X, Montague BT, Rich JD, et al. HIV care after jail: low rates of engagement in a vulnerable population. *J Urban Health*. 2018;95(4):488–98.
- Carroll M, Nassau T, Miller M, Poerio C, Zellman R, Herdman B, et al. Improved HIV care outcomes for inmates referred to community programs in Philadelphia. Seattle; 2017. Available from: http://www.croiconference.org/sites/default/files/posters-2017/911_Carroll.pdf. Cited 2019 Feb 7.
- Westergaard RP, Hochstatter KR, Andrews PN, Kahn D, Schumann CL, Winzenried AE, et al. Effect of patient navigation on transitions of HIV care after release from prison: a retrospective cohort study. *AIDS Behav*. 2019; 23(9):2549–57.
- Loeliger KB, Meyer JP, Desai MM, Ciarleglio MM, Gallagher C, Altice FL. Retention in HIV care during the 3 years following release from incarceration: a cohort study. *PLoS Med*. 2018;15(10):e1002667.
- Giordano TP, Gifford AL, White AC, Almazor MES, Rabeneck L, Hartman C, et al. Retention in care: a challenge to survival with HIV infection. *Clin Infect Dis*. 2007;44(11):1493–9.
- Tripathi A, Youmans E, Gibson JJ, Duffus WA. The impact of retention in early HIV medical care on Viro-immunological parameters and survival: a statewide study. *AIDS Res Hum Retrovir*. 2011;27(7):751–8.
- Wohl DA, Rosen DL. Inadequate HIV care after incarceration: case closed. *Lancet HIV*. 2018;5(2):e64–5.
- Yehia BR, Ketner E, Momplaisir F, Stephens-Shields AJ, Dowshen N, Eberhart MG, et al. Location of HIV diagnosis impacts linkage to medical care. *J Acquir Immune Defic Syndr* 1999. 2015;68(3):304–9.
- Muessig KE, Rosen DL, Farel CE, White BL, Filene EJ, Wohl DA. "Inside these fences is our own little world": prison-based HIV testing and HIV-related stigma among incarcerated men and women. *AIDS Educ Prev*. 2016;28(2): 103–16.
- Chen NE, Meyer JP, Avery AK, Draine J, Flanigan TP, Lincoln T, et al. Adherence to HIV treatment and care among previously homeless jail detainees. *AIDS Behav*. 2013;17(8):2654–66.
- Myers JJ, Kang Dufour M-S, Koester KA, Morewitz M, Packard R, Monico Klein K, et al. The effect of patient navigation on the likelihood of engagement in clinical care for HIV-infected individuals leaving jail. *Am J Public Health*. 2018;108(3):385–92.
- Rich JD. Successful linkage of medical care and community services for HIV-positive offenders being released from prison. *J Urban Health Bull N Y Acad Med*. 2001;78(2):279–89.
- Zaller ND, Holmes L, Dyl AC, Mitty JA, Beckwith CG, Flanigan TP, et al. Linkage to treatment and supportive services among HIV-positive ex-offenders in project bridge. *J Health Care Poor Underserved*. 2008;19(2):522–31.
- Spaulding AC, Booker CA, Freeman SH, Ball SW, Stein MS, Jordan AO, et al. Jails, HIV testing, and linkage to care services: an overview of the EnhanceLink initiative. *AIDS Behav*. 2013;17(5):100–7.
- Booker CA, Flygare CT, Solomon L, Ball SW, Pustell MR, Bazerman LB, et al. Linkage to HIV care for jail detainees: findings from detention to the first 30 days after release. *AIDS Behav*. 2013;17(Suppl 2):S128–36.
- Cunningham WE, Weiss RE, Nakazono T, Malek MA, Shoptaw SJ, Ettner SL, et al. Effectiveness of a peer navigation intervention to sustain viral

suppression among HIV-positive men and transgender women released from jail: the LINK LA randomized clinical trial. *JAMA Intern Med.* 2018; 178(4):542.

42. Khawcharoenporn T, Cole J, Claus J, Bell T, Lewis A, Zawitz C, et al. A randomized controlled study of intervention to improve continuity care engagement among HIV-infected persons after release from jails. *AIDS Care.* 2018;10:1–8.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

